Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

By LabMedica International staff writers
Posted on 11 Jul 2025

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. More...

These treatments not only target cancerous areas but also damage healthy tissues, causing side effects that can severely affect patients’ quality of life. Additionally, the treatment often fails to precisely target cancer cells, leading to resistance and recurrence. To overcome these limitations, nanomaterial-based cancer treatments have emerged as a promising solution. However, most current nanomaterials focus on a single function, limiting their therapeutic potential. Now, researchers have developed a new nanomaterial that is capable of simultaneously performing cancer diagnosis, treatment, and immune response induction, paving the way for a next-generation treatment platform.

Scientists at the Korea Research Institute of Standards and Science (KRISS, Daejeon, South Korea) have developed a new triple-layer nanodisk (AuFeAuNDs) that offers multiple therapeutic mechanisms in a single material. The design of the nanodisk, which features iron at the core of a gold structure, provides superior stability compared to traditional spherical materials. The nanodisk is equipped with photoacoustic (PA) imaging capabilities, which allow real-time monitoring of both tumor location and drug delivery. By using a magnet near the tumor site, the nanomaterial's magnetic properties enable precise targeting.

In addition, the material performs three types of cancer therapies: photothermal therapy (PTT), chemical dynamic therapy (CDT), and ferroptosis therapy. This multifunctionality is combined with immune response activation, triggering the release of danger-associated molecular patterns (DAMPs) from cancer cells, which helps the immune system recognize and attack recurring cancer cells.

The nanodisk was tested in animal experiments, where PA imaging successfully tracked the accumulation of nanoparticles at the tumor site. The research team confirmed that the optimal treatment time is 6 hours after administering the material. Additionally, the nanodisk induced a significant increase in immune cell count, with up to three times more immune cells identified after treatment. These results highlight the potential of this nanomaterial for improving the effectiveness of cancer treatments and inducing immune responses against cancer recurrence.

The study's findings, published in Chemical Engineering Journal, suggest that this innovative nanomaterial could serve as a platform for next-generation cancer therapy. Future research will focus on optimizing the material's effectiveness in human trials and exploring additional therapeutic applications.

“Unlike conventional nanomaterials, which are composed of a single element and perform only one function, the material developed in this study utilizes the combined properties of gold and iron to perform multiple functions,” said Dr. Lee Eun Sook from KRISS.

Related Links:
KRISS


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.